Elanco's Q1: Fire Numbers, Innovation, and Growth

Elancos Q1 Results: A Blazing Performance Elancos first quarter numbers are nothing short of impressive, with revenue reaching $1.371 billion, a 15% increase reported and 10% organic constant currency. The company surpassed guidance on revenue, adjusted EBITDA, and earnings per share, thanks to price hikes and volume across pets and farm animals in every major region. Innovation products alone contributed $287 million. Pet health led the charge with 6% growth in the U.S. despite winter storms, accelerating to 8% in March and even stronger in April. Standout products like Zenrelia and Credelio Quattro gained market share in parasiticides and dermatology, while international pet saw 9% gains from those same hits plus Adtab. Farm animal popped 15% in the U.S. and 13% overseas, driven by poultry and cattle. Executives are thrilled with the teams execution, highlighting market share wins in key categories and a strong base business. Pet owners are dealing with record tick bites, setting the stage for a robust parasite season, and over two million dogs now on Zenrelia demonstrate real demand. This momentum has boosted the entire portfolio, even as they deleveraged to 3.5 times net leverage. Elanco is raising full-year guidance: 5-7% organic growth, adjusted EBITDA of $975 million to $1.005 billion, and EPS of $1.03 to $1.09. The innovation target has been increased to $1.2 billion, with Big Six products on track to double by 2028. Befrena is set to launch soon, and label tweaks for Zenrelia are in the works. Elanco is well-positioned with their innovation pipeline, productivity push via Elanco Ascend, and capitalization on mega-trends in animal health, ensuring sustained growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3c8733693b2f4909